APLS
USDApellis Pharmaceuticals Inc. Common Stock
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$20.400
Máximo
$20.610
Mínimo
$19.440
Volumen
5.10M
Fundamentos de la Empresa
Capitalización de Mercado
2.5B
Industria
Biotecnología
País
United States
Estadísticas de Negociación
Volumen Promedio
2.51M
Bolsa
NMS
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Mizuho Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $19
Mizuho analyst Graig Suvannavejh maintains Apellis Pharmaceuticals with a Neutral and lowers the price target from $24 to $19.
Citigroup Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $52 to $45.
TD Cowen Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
TD Cowen analyst Phil Nadeau maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $50 to $45.
Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $52
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals with a Outperform and raises the price target from $50 to $52.
HC Wainwright & Co. Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $45
HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals with a Buy and lowers the price target from $57 to $45.
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary
Wells Fargo Upgrades Apellis Pharmaceuticals to Overweight, Raises Price Target to $32
Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals from Equal-Weight to Overweight and raises the price target from $29 to $32.
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.